Why did Atossa Therapeutics Inc. (ATOS) underperform on Thursday?

SWAV stock
SWAV stock

Atossa Therapeutics Inc. (ATOS) shares fell 5.38% in after-hours on Thursday, July 29, 2021, and closed the daily trading at $3.69 per share. Earlier in the regular trading on Thursday, ATOS’s stock lost 1.27%. ATOS shares have fallen 10.34% over the last 12 months, and they have moved down by 5.11% in the past week. Over the past three months, the stock has gained 68.10%, while over the past six months, it has declined 87.50%. The company has a current market of $471.21 million and its outstanding shares stood at 120.82 million.

Let’s discuss its recent news and developments briefly.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.


>> 7 Top Picks for the Post-Pandemic Economy << 

ATOS received approval for the AT-H201 clinical study in Australia

On July 07, 2021, Atossa Therapeutics, Inc (ATOS) received regulatory approval from HREC (Human Research Ethics Committee) to open a clinical study of AT-H201 in Australia. The nebulized formulation, AT-H201, is being developed as an inhalation therapy for moderately to severely ill hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease.

Read More

ATOS Induction on Russell 2000 and Russell 3000 Indexes

On June 28, 2021, Atossa Therapeutics, Inc was added to the Russell 2000 and Russell 3000 Indexes, according to a preliminary list of additions posted June 4, and June 14, 2021.

Swedish regulators Approved phase 2 study of ATOS Endoxifen

On June 11, 2021, Atossa Therapeutics, Inc (ATOS) received approval from the Swedish Medical Product Agency (MPA) to initiate a Phase 2 clinical study of its oral Endoxifen for the reduction of mammographic breast density (MBD).

What is MDB?

MBD is an emerging public health issue affecting more than 10 million women in the United States and many more worldwide. Studies conducted by others have shown that MBD reduces the ability of mammograms to detect cancer (sensitivity) and increases the risk of developing breast cancer. Additional studies show a correlation between reducing MBD and a reduction in the incidence of breast cancer.

Final Data from Phase 2 Study of Endoxifen

On June 09, 2021, Atossa Therapeutics, Inc announced the final data from its Phase 2 clinical study of oral Endoxifen administered in the “window of opportunity” between diagnosis of breast cancer and surgery.

The primary endpoint was achieved by reducing 65.1% Ki-67 from an average of 25.6% at the screening to 6% on the day of surgery, a 65.1% reduction.

All adverse events were mild and considered related to the study drug. Endoxifen was considered safe and well-tolerated in this study. No adverse events led to the discontinuation of the study.

>> 7 Top Picks for the Post-Pandemic Economy << 


As of this writing, we have no recent news which could justify ATOS bad performance on Thursday. we hope that it will end the weekly trading on a positive note.


Please enter your comment!
Please enter your name here